Longboard Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
Longboard Pharmaceuticals, Inc. carries a market capitalization of 2.34B, placing it among publicly traded companies globally. Its enterprise value stands at 972.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.34B |
| Enterprise Value | 972.49M |
Share Statistics
Longboard Pharmaceuticals, Inc. currently has 39.03M shares outstanding.
| Shares Outstanding | 39.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -6.23 |
| P/TBV Ratio | 4.57 |
| P/FCF Ratio | -19.07 |
| P/OCF Ratio | -19.07 |
Financial Position
Longboard Pharmaceuticals, Inc. maintains a current ratio of 15.97, meaning it holds 16.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.97 |
| Quick Ratio | 15.72 |
| Debt / Equity | 1.36 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -42.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Longboard Pharmaceuticals, Inc.'s stock has gained approximately 894.6932% over the past 52 weeks. The 50-day moving average sits at - -, while the 200-day moving average is - -.
| Beta (5Y) | N/A |
| 52-Week Price Change | 894.6932% |
| 50-Day Moving Average | - - |
| 200-Day Moving Average | - - |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -87.44M, while operating income came in at -87.45M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -87.45M |
| Pretax Income | -76.34M |
| Net Income | -76.34M |
| EBITDA | -87.44M |
| EBIT | -87.45M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
Longboard Pharmaceuticals, Inc. holds 288.45M in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -27.61M. Total book value stands at -201.87M, with working capital of 274.68M providing operational flexibility.
| Cash & Cash Equivalents | 288.45M |
| Total Debt | 3.73M |
| Net Debt | -27.61M |
| Equity (Book Value) | -201.87M |
| Book Value Per Share | -5.35 |
| Working Capital | 274.68M |
Cash Flow
Longboard Pharmaceuticals, Inc. produced -65.93M in operating cash flow over the past twelve months.
| Operating Cash Flow | -65.93M |
| Capital Expenditures | N/A |
| Free Cash Flow | -65.93M |
| FCF Per Share | -1.75 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.07 |
| FCF Yield | -5.24 |
Scores
Longboard Pharmaceuticals, Inc. posts an Altman Z-Score of 33.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 33.76 |